anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/EP95/01045 Sec. 371 Date Sep. 10, 1996 Sec. 102(e) Date Sep. 10, 1996 PCT Filed Mar. 21, 1995 PCT Pub. No. WO95/26344 PCT Pub. Date Oct. 5, 1995The present invention concerns novel compounds obtained by fermenting a microorganism of the genus Memnonoiella or Stachybotrys, which compounds are inhibitors of the enzyme inositol monophosphatase (EC 3.1.3.25). The present invention also relates to the use of these novel compounds in treating manic depression and pharmaceutical formulations comprising said compounds as active ingredient; a further object is the use of these compounds in an analytical method for detecting inositol monophosphatase.
Use of 10% P-I swabstick to sterilize the ocular surface and surrounding lids and eyelashes only, prior to injection. Intervention: bacterial culture swab.
This is a single center prospective, randomized study with a crossover design, comparing two low profile balloon gastrostomy buttons (Figure 1), MIC-Key™ and MINI One™ that are routinely used at CMH. Each subject will be randomly assigned to one button type at the time of initial placement. After placement, standard practice is to perform the first gastrostomy change in the clinic at 2 months where the primary caregivers replace the button under supervision. Therefore, the initial device after randomization will remain in place for 2 months. At the first scheduled device change, the other type of button will replace the original gastrostomy button device. This will remain in place for another 2 months. At the routine visit at 4 months the parents will be asked to choose which button they prefer to keep. This will meet the primary outcome endpoint of the study. The investigators will continue to follow as many subjects as possible to 4 years in order to identify any potential differences in secondary end points.

A caregiver satisfaction survey is routinely used in the clinics. Parent responses to this survey will be also be used in the study analysis.
Pituitary suppression will be achieved by long or antagonist protocol. For long protocol, GnRH agonist will be administered for 10-14 days starting from mid-luteal phase of preceding cycle. After confirmation of down regulation, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). Gonadotropins therapy will be tailored according to age, BMI, antral follicle count, antimullerian hormone and previous response. In antagonist protocol, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). GnRH antagonist will be adjusted according to patient response. On the 5th -6th day of stimulation, sonography will be performed and repeated every 1-3 days with regular estradiol assessment. When at least 3 follicles reach ≥ 17 mm in mean diameter, trigger will be given. Oocytes pick up will be performed 34-36 hour after triggering.
The invention belongs to the technical field of biological medicines, and particularly relates to a bailquinone derivative and application thereof in preparing an AMPK activator and a medicine for treating breast cancer. The present invention provides a bailquinone derivative shown in formula I. The invention also provides a synthesis method of the compound shown in the formula I. The compounds provided by the invention (e.g., TQFL 12) are capable of significantly inhibiting the growth, migration and invasion of breast cancer cells, and have specific cytotoxicity to Triple Negative Breast Cancer (TNBC) cells. And the TQFL12 has significantly stronger inhibition effect on breast cancer cells than that of the bailquinone (TQ). Thus, TQFL12 has potential as a drug for treating breast cancer. In addition, TQFL12 activates AMPK/ACC signaling pathway expression at the protein level by stabilizing AMPK alpha. Thus, TQFL12 can also act as an AMPK activator.
The invention relates to an SSR-labeled fingerprint of shiitake mushroom Guangxiang strain, and an application thereof. The fingerprint is composed of 7 pairs of SSR-labeled specific allelic fragments developed according to a shiitake mushroom genomic sequence. The application comprises the steps that: SSR-labeled amplification is carried out upon a shiitake mushroom strain; and an obtained band type is compared with the fingerprint. If the band type is consistent with the fingerprint, the strain is a shiitake mushroom Guangxiang strain. Compared with a conventional morphological detection method, an antagonistic test, and mushroom fruiting trials, the application provided by the invention has the advantages of short detection time, high accuracy, and good repeatability. In 25 collected nationally validated shiitake mushroom main cultivated strains of our nation, the fingerprint has shiitake mushroom Guangxiang strain specificity.
Enhanced Recovery After Surgery (ERAS) is an interdisciplinary, multimodal concept and has become an important focus of Pancreaticoduodenectomy procedures following universal accepted and practice in gastrointestinal and colorectal surgeries. Early oral diet without restrictions after operation is recommended strongly according to ERAS guideline. However, several studies demonstrated that only half validated the true practice of the postoperative oral diet. Furthermore, Oral intake tolerance after PD is controversial. Only 23% of patients were able to take solid food at day 3. It appears that adequate nutritional intake only via oral diet is a severe challenge. Besides, Studies showed that insufficient amount of dietary intake was significantly associated with extended duration of postoperative hospitalization and parenteral nutrition. Importantly, Specific clinical study on early oral intake after PD is very limited. Therefore, the present study is aim to evaluate the tolerance, safety, and efficacy in the patients undergoing PD in the age of ERAS.
BACKGROUND: Tetanus is a life-threatening but preventable neurologic disorder characterized by trismus and muscle spasms. Despite its decreasing global incidence, it remains to be endemic in resource-limited settings such as the Philippines. This study aimed to determine the incidence, demographic characteristics, risk factors, clinical presentation, management, complications, and outcomes of non-neonatal tetanus cases in a tertiary hospital in the Philippines. It also aimed to compare the clinical profile and outcomes between the adult and pediatric subgroups.
METHODS: This study used a retrospective cross-sectional design including all adult and pediatric non-neonatal tetanus patients admitted at the University of the Philippines - Philippine General Hospital from January 2012 to June 2023. Data was extracted from department censuses and inpatient charts.
RESULTS: One hundred thirty-eight cases were included. The incidence rate was 0.03%, while mortality rate was 29%. Majority of patients were males presenting with trismus and spasms after sustaining a puncture wound. Chronic hypertension was associated with an increased hazard of death by 4.5 times (p = 0.004), while treatment with magnesium sulfate was associated with a decreased hazard of death by 35 times (p = 0.005). The mode of infection and the medications administered differed between the adult and pediatric subgroups.
CONCLUSIONS: Although the total number of cases has decreased over the past decade, tetanus remains to have a high incidence and mortality rate in the Philippines. Increasing vaccination coverage, improving public awareness, and educating health professionals can help reduce morbidity and mortality from this disease.
FIELD: animal husbandry. ^ SUBSTANCE: invention refers to feeding cats and dogs. Here is disclosed a diet composition intended for feeding young domestic animals; the composition includes sulphur containing anti-oxidant different from lipoic acid. The method of increasing levels of contents of anti-oxidant in blood of cats is achieved by feeding cats with effective amount of diet composition. ^ EFFECT: invention facilitates increasing level of anti-oxidant contents in organism of cats and dogs. ^ 20 cl, 3 tbl, 1 ex
BACKGROUND AND OBJECTIVE: Limited understanding exists regarding the factors affecting the prognosis of surgical treatment for type 2 diabetes mellitus (T2DM), particularly in Chinese patients. In this study, we examined a cohort of early and intermediate obese T2DM patients to explore the potential impact of preoperative lipid metabolism in metabolic surgery on the postoperative remission of T2DM.
METHODS: Participants with T2DM and obesity underwent metabolic surgery. Clinical data, including baseline body mass index, percentage of excess weight loss, and preoperative biochemical indicators, were collected and analyzed. A multidisciplinary team conducted patient follow-up. Remission was defined as sub-diabetic hyperglycemia (HbA1c < 48 mmol/mol, fasting glucose 100-125 mg/dl) without pharmacological intervention for at least 12 months.
RESULTS: Over a median follow-up of 27 months, 96 T2DM patients with metabolic surgery were studied, with no laparotomies required. Among these patients, 61 (63.5%) achieved complete remission, and 85 (88.5%) experienced remission. In multivariable analysis models, preoperative fasting blood glucose (FBG) significantly correlated with all postoperative outcomes. Furthermore, mediation analysis indicated that preoperative triglycerides (TG) mediated 26.31% of the association between preoperative FBG and postoperative remission. Both preoperative FBG and TG were negatively associated with the postoperative remission of T2DM.
CONCLUSION: In summary, our findings suggest that lower preoperative fasting glucose levels enhance the likelihood of postoperative T2DM remission. Moreover, preoperative TG could potentially play a mediating role in the postoperative remission of T2DM. Therefore, evaluating and managing fasting glucose and lipids before the procedure may aid in assessing the prognosis of metabolic surgery. Level of evidence Level III, designed cohort.
Advanced Cognitive Stimulation Therapy (ACST), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. ACST will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee or care home staff.
This Randomized Control Trial will be conducted to compare the effects of various heights of anterior power arm on maxillary anterior dentition following en masse retraction with mini-implants by participation of thirty patients meeting eligibility criteria. The participants will be divided in three groups through software generated randomization table. Group I (control group; height of anterior power arm 6 mm), Group II and Group III (experimental groups; height of anterior power arm 3 mm and 9 mm, respectively). Ten patients will be allocated in each group. En masse retraction with mini implants and various heights of anterior power arm will be carried out immediately after bilateral maxillary first premolar extractions using continuous arch sliding mechanics. Horizontal, vertical and angular dimensions will be measured on lateral cephalograms while the transverse effects will be measured on maxillary dental cast. Both lateral cephalograms and dental casts will be obtained at two different point of time; T1, before retraction and T2, after complete extraction space closure. The data will be assessed with-in and among groups.
Percutaneous coronary intervention (PCI) has dramatically changed the treatment of obstructive coronary artery disease patients. PCI is indicated in patients with chronic coronary syndrome (CCS) symptoms unresponsive to optimized medical therapy. The American College of Cardiology Foundation and partners developed in 2009 - and updated them in May 2017 - the appropriateness criteria for PCI to support the rational use of PCI in chronic patients and to provide patients with high-quality cardiovascular care. Since then, these criteria have been applied to guide physicians and serve as metrics of the quality of care based on the best available scientific evidence. Countries like the United States and Japan already have robust studies on the topic with important repercussions on clinical practice. In Brazil, to date, there are no studies on the adequacy of PCIs in patients with CCS.

The primary goal of the RIGHT-PCI study is to determine the rate of PCI indications categorized as appropriate, possibly appropriate, or rarely appropriate in patients with CCS undergoing elective PCI based on criteria established in medical literature at a Cardiology reference university hospital. To achieve this objective, we plan to analyze approximately 2,500 consecutive angioplasties performed between 2017 and 2020.
Colon cancer (CC) is a malignant disease of the digestive tract, and its rising prevalence poses a grave threat to people's health. N6-methyladenosine (m6A) modification is essential for various crucial life processes through modulating gene expression. Methyltransferase-like 14 (METTL14), the m6A methylation transferase core protein, and its aberrant expression is intimately correlated to tumor development. This study was conducted to probe the impacts and specific mechanisms of METTL14 on the biological process of CC. Bioinformatics data disclosed that METTL14 was significantly attenuated in CC. Functional assays were executed to ascertain how METTL14 affected CC tumorigenicity, and METTL14 overexpression caused a notable decline in viability, migration, invasion, and stemness phenotype of CC cells. Then, in-depth mechanistic studies displayed that stearoyl-CoA desaturase 1 (SCD1) was a downstream target gene of METTL14-mediated m6A modification. METTL14 overexpression substantially augmented the m6A modification of SCD1 mRNA and diminished the SCD1 mRNA level. In addition, we revealed that YTHDF2 was the m6A reader to recognize METTL14 m6A-modified SCD1 mRNA and abolish its stability. Finally, we also validated that METTL14 might impede the tumorigenic process of CC through SCD1 mediated Wnt/β-catenin signaling. Taken together, this study presented that METTL14 performed as a potential therapeutic target in CC with important implications for the prognosis amelioration of CC patients.
Patients in the SER group (Progressive upright positioning protocol) will receive standard physiotherapy including passive range of motion exercises, active exercises, bed mobility, and respiratory therapy during their ICU stays. In the SER group, out-of-bed mobilization (\>=Level III in the Modified Trauma ICU Mobility Scale) will be started as soon as possible after ICU discharge but at least Level III (sitting on the edge of bed) above 7 days of onset.
Pharmaceutical compositions contg. cyclosporins contain one or more cyclosporins, one or more natural oils, 3-sn-phosphatidyl choline and/or phosphatidyl ethanol amine and water.     The compositions also contain pharmaceutically acceptable fatty acids and/or alkali salts of free fatty acids. The cyclosporin is a natural and/or synthetic cyclosporin deriv., pref. cyclosporin A and/or G and/or SDZ 1MM 125. The 3-sn-phosphatidyl choline is in the form of a 3-sn-phosphatidyl choline contg. substance, pref. egg or soya lecithin, and can be partially or completley hydrogenated.
The project prospectively collected the clinical information of patients in general surgery (gastrointestinal surgery, biliary surgery, pancreatic surgery), noninvasively monitored the patient's temperature, heart rate, ECG, respiratory rate through the body surface with wireless vital signs sensor, guided the patient to wear correctly from the first day of admission, and continuously monitored the patient's preoperative, intraoperative and postoperative vital signs throughout the whole process until leave hospital，The traditional "point" vital signs monitoring will be updated to continuous "line" monitoring, returning to the real world of patients' vital signs. The vital signs data of patients are continuously collected, transmitted in real-time and stored in the local central workstation of the ward, and the researchers of the project are specially assigned to be responsible for data export, storage and analysis. In view of the lack of early warning means for acute and critical complications in surgical ward, wearable devices with verified accuracy were used to collect continuous vital signs big data, fully mining the internal relationship between the change trend of patients' multiple vital signs parameters and complications, and establishing an intelligent risk warning model for perioperative complications of surgical patients, It lays the foundation for the establishment of a higher-level real-time patient risk warning and clinical decision support system, so as to improve the perioperative safety of patients and promote the penetration of artificial intelligence in clinical medicine and nursing.

Participants will use the Clavien Dindo grading criteria to determine the severity of complications according to the Cohort study method. According to whether the patient has experienced complications and the type of complications, the patient is divided into different subgroups and the patient outcome is manually calibrated. Mining the change trend of patient's vital signs over time, Convolutional neural network is used to extract morphological features from the continuous vital sign curves of the past 24 hours, and two-way short-term memory neural network is used to extract temporal features to obtain two sets of feature vectors. All data are feature fused, and sparse features are specially processed, and then sent to another weighted recurrent neural network to establish a complication prediction model, and predict the patient's Respiratory failure risk level, ICU risk level, and death risk level in the next 24 hours. Continuously revise the algorithm and set alarm threshold logic based on personal baseline data. Compare the predictive power of this model with the predictive power obtained from the national warning score NEWS, and determine the sensitivity, specificity, false positive rate, false negative rate, positive predictive value, and negative predictive value of the two in predicting patient outcomes.
In the large-scale production of rabies vaccine a cell stock comprising a VERO cell strain and a liquid nutritive medium containing serum and microcarriers suspended therein is successively passed into biogenerators of increasing volume. The last of the passages is carried out in a biogenerator having a volume of at least 150 liters. The liquid nutritive medium is drawn off at the end of the final passage and replaced with a serum-free liquid nutritive medium. The cell stock is inoculated in the last passage biogenerator with virus which is allowed to develop. The virus is then cultured, withdrawn and filtered. The filtered liquid suspension is then ultrafiltered, with inactivated beta-propiolactone and purified by zonal centrifugation or chromatography.
Rationale: Hereditary fructose intolerance (HFI) is a rare inborn error of metabolism. Patients with HFI develop acute abdominal pain, nausea, vomiting, hypoglycemia and proximal tubular dysfunction upon consumption of a fructose containing food product. In rare cases, (prolonged) fructose consumption can even lead to liver and kidney failure. Patients with HFI are therefore treated with a lifelong fructose-restricted diet. Animal studies have shown that the clinical manifestations of HFI are abrogated upon inhibition of ketohexokinase (KHK), the enzyme that catalyses the first step in fructose metabolism.

Recently, PF-06835919, a KHK inhibitor (KHKi), was developed as a new treatment for non-alcoholic fatty liver disease. The compound was well tolerated in several phase II clinical trials.

It is hypothesized that PF-06835919 is also effective in patients with HFI. Objective: To study the effects of PF-06835919 on fructose tolerance and intrahepatic lipid content in patients with HFI. Study design: open-label, pilot study Study population: three adult patients with HFI will be treated with PF-06835919. Five adult healthy individuals will be included (but not be treated) as a reference. Intervention (if applicable): Patients receive once daily (in the morning) three tablets of 100 mg PF-06835919 for 9 days. They will subsequently be gradually exposed to increasing doses of either oral fructose or glucose (in a blinded fashion). Healthy individuals will only undergo oral fructose exposure, as a reference. Main study parameters/endpoints: Intrahepatic lipid content assessed by proton magnetic resonance spectroscopy (at baseline and completion), intestinal fructose tolerance (after oral fructose in comparison to oral glucose), hepatic fructose tolerance (serum glucose and phosphate after oral fructose in comparison to healthy individuals) and renal fructose tolerance (urinary glucose, phosphate, pH and amino acids after oral fructose in comparison to healthy individuals). Nature and extent
Patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders, including severe constipation, or major GI tract surgery were not included in the sevelamer carbonate clinical studies.

Cases of dysphagia and esophageal tablet retention have been reported in association with use of the tablet formulation of sevelamer, some requiring hospitalization and intervention. Consider using sevelamer suspension in patients with a history of swallowing disorders. 

Cases of bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have also been reported with sevelamer use [see Adverse Reactions (6.2)]. Inflammatory disorders may resolve upon sevelamer discontinuation. Treatment with sevelamer should be re-evaluated in patients who develop severe gastrointestinal symptoms.
N 6,2'-O-dimethyladenosine (m6Am) is a prevalent modification frequently found at the 5' cap-adjacent adenosine of messenger RNAs (mRNAs) and small nuclear RNAs (snRNAs) and the internal adenosine of snRNAs. This dynamic and reversible modification is under the regulation of methyltransferases phosphorylated CTD interacting factor 1 and methyltransferase-like protein 4, along with the demethylase fat mass and obesity-associated protein. m6Am RNA modification plays a crucial role in the regulation of pre-mRNA splicing, mRNA stability, and translation, thereby influencing gene expression. In recent years, there has been growing interest in exploring the functions of m6Am and its relevance to human diseases. In this review, we provide a comprehensive overview of the current knowledge concerning m6Am, with a focus on m6Am-modifying enzymes, sequencing approaches for its detection, and its impacts on pre-mRNA splicing, mRNA stability, and translation regulation. Furthermore, we highlight the roles of m6Am in the context of obesity, viral infections, and cancers, unravelling its underlying regulatory mechanisms.